Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
06:16pm, Wednesday, 28'th Dec 2022 PennyStocks
Penny stocks to watch this week.
The post Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
01:16pm, Wednesday, 28'th Dec 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
07:41pm, Thursday, 08'th Dec 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.
The Dow traded up 0.27% to 33,689.58 while the NASDAQ rose 0.92% to 11,059.06. The S&P 500 a
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
05:56pm, Thursday, 08'th Dec 2022 Benzinga
Gainers
My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Pharvaris N.V. (NASDAQ: PHVS) shares climbed 56.7% to $4.0914 after the company r
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
05:12pm, Thursday, 08'th Dec 2022 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded up 0.61% to 33,803.12 while the NASDAQ rose 0.93% to 11,060.62. The S&P
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
03:03pm, Thursday, 08'th Dec 2022 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.49% to 33,763.59 while the NASDAQ rose 0.35%
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on
Eiger BioPharmaceuticals: A Compelling High Beta Story
02:58am, Saturday, 26'th Nov 2022
Today, we revisit the investment case around Eiger BioPharmaceuticals for the first time in more than a year and a half. Eiger has one product on the market and is rapidly advancing a powerful 'sum of
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript
09:25pm, Thursday, 03'rd Nov 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - P
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
07:35pm, Thursday, 03'rd Nov 2022
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
12:35pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
01:40pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Dow falls 300 points after best start to a quarter since 1938
03:28pm, Wednesday, 05'th Oct 2022 MarketWatch
U.S. stocks trade lower on Wednesday as a more cautious tone prevailed following a strong start to the fourth quarter.
A strong fall COVID booster campaign could save 90,000 U.S. lives and avoid more than 936,000 hospitalizations, study finds
01:53pm, Wednesday, 05'th Oct 2022 MarketWatch
A strong fall COVID booster campaign could save about 90,000 people living in the U.S. from dying of the virus and avoid more than 936,000 hospitalizations, according to a new study by the Commonwealt
Eiger's stock falls 20% after telling investors it won't seek FDA authorization for COVID-19 drug
08:42am, Wednesday, 05'th Oct 2022
Shares of Eiger BioPharmaceuticals Inc. EIGR, -1.20% tumbled 20.4% in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for
